Applovin Corporation vs Zoetis Inc — how do they compare? Applovin Corporation trades at $315 (market cap $106.65B), while Zoetis Inc trades at $72.65 (market cap $31.14B). The key difference: Applovin Corporation is far larger — about 3.4× Zoetis Inc's market cap, and Zoetis Inc pays a 2.81% dividend while Applovin Corporation pays none. Which is the better fit depends on your goals.
| APP | ZTS | |
|---|---|---|
Market Cap | $106.65B | $31.14B |
Sector | Technology | Health |
52-Week High | $733.60 | $156.76 |
52-Week Low | $318.68 | $71.91 |
Enterprise Value | $107.11B | $38.70B |
Dividend Yield | — | 2.81% |
Signals from Pluang's Aura AI — not financial advice
AppLovin (APP) trades at $313.50, down 7.52% in the last 24 hours, reflecting recent volatility after a Q2 2026 revenue miss. The stock is technically bearish with key support at $306, while fundamentals remain strong with 53% YoY revenue growth, 64.58% net income margin, and robust cash flow. Recent news highlights a Bank of America downgrade to Neutral, citing uncertainty around sustaining 30% long-term revenue growth, contributing to negative sentiment despite strong profitability.
The outlook is mixed: strong fundamentals and an 80.77% analyst buy rating with a $556.53 consensus price target suggest significant upside, but execution risks and growth sustainability concerns pose near-term headwinds. Investors face a trade-off between attractive valuation multiples and potential volatility from competitive and operational challenges in the ad-tech sector.
Zoetis (ZTS) trades at $74.86, up 3.03% today but facing bearish technical signals with 16 sell indicators. The company reported mixed Q2 2026 results, beating EPS estimates but missing revenue expectations, while cutting full-year guidance due to softer pet healthcare demand. Strong fundamentals include a 27.69% net margin and 64.91% ROE, though valuation metrics show a P/E of 12.29 and P/S of 3.41.
The stock presents a value opportunity with analyst consensus target of $94.90 (27% upside), but faces near-term headwinds from competitive pressures and class action lawsuits. Investors should weigh strong profitability against slowing growth in companion animal segments and technical bearishness.
Trailing returns across standard periods
Latest headlines on both assets
AppLovin provides a software platform for mobile app developers to market, monetize, and analyze their apps. Its AI-powered tools help developers grow their business by connecting them with global advertising networks.
Read more on APP →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →